RxDoctor Payments Data

Jackson Maille, MD

Family Medicine · Wallingford, CTNPI 1255443479

Payments from drug & device makers

$4,894in general payments, 2019–2025

Across 139 payments — averaging $35.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$786
  • Amgen$775
  • Boehringer Ingelheim$470
  • Abbott$243
  • Bayer$191
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$4,886100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,894 in reported general payments places this provider in the 85th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$32,862
Medicare patients
95
Services billed
464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$88,674
JardianceEmpagliflozin30$47,866
FarxigaDapagliflozin Propanediol45$47,667
JanuviaSitagliptin Phosphate27$39,866
EliquisApixaban44$34,368
TradjentaLinagliptin25$26,209
EntrestoSacubitril/Valsartan16$22,202
TrulancePlecanatide16$14,499
Clomipramine Hcl36$14,242
SavellaMilnacipran Hcl14$12,354
LinzessLinaclotide22$11,987
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$11,186
MyrbetriqMirabegron12$9,559
Tresiba Flextouch U-100Insulin Degludec13$6,680
Quetiapine Fumarate62$4,287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,367$88,67489 claims
Boehringer IngelheimJardiance, Tradjenta$470$74,07455 claims
AstraZenecaFarxiga$123$47,66745 claims
PfizerEliquis$130$34,36844 claims
AbbVieSavella, Linzess$786$24,34136 claims
GSKAnoro Ellipta$125$11,18623 claims
Lilly USA, LLCOlanzapine$140$1,58622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Wallingford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →